Switch to an Alternative SGLT2 Inhibitor
Yes, you can and should switch him to an alternative SGLT2 inhibitor—specifically empagliflozin 10 mg daily or dapagliflozin 10 mg daily—as these provide equivalent cardiovascular and renal benefits to canagliflozin (Invokana) while maintaining glycemic control. 1
Why Continue SGLT2 Inhibitor Therapy
Your patient was previously better controlled on the combination of metformin and Invokana, indicating he responds well to SGLT2 inhibitor therapy. SGLT2 inhibitors with proven cardiovascular benefit are strongly recommended for patients with type 2 diabetes regardless of baseline A1c or cardiovascular disease status 1, 2. The cardiovascular and renal benefits of SGLT2 inhibitors are independent of their glucose-lowering effects 3.
Specific Alternative Options
First-Line Alternatives (Preferred):
Empagliflozin 10 mg once daily 4, 1
- Proven cardiovascular mortality reduction in EMPA-REG OUTCOME trial
- Similar efficacy to canagliflozin for glycemic control
- Lower amputation and fracture risk compared to canagliflozin 4
Dapagliflozin 10 mg once daily 1, 2
- Proven benefits in heart failure and chronic kidney disease
- Can be used down to eGFR ≥25 mL/min/1.73 m² 1
- No increased amputation risk 4
Key Differences from Canagliflozin:
Canagliflozin carries specific FDA warnings for increased risk of lower limb amputations and bone fractures that are not seen with empagliflozin or dapagliflozin 4, 5. This makes empagliflozin or dapagliflozin safer alternatives, particularly if your patient has any peripheral vascular disease, neuropathy, or osteoporosis risk factors.
Practical Switching Considerations
Direct switch without titration: Simply discontinue Invokana 100 mg and start empagliflozin 10 mg or dapagliflozin 10 mg the next day. No washout period or dose adjustment needed 1.
Monitor for:
- Volume depletion symptoms (lightheadedness, orthostasis) in the first 2-4 weeks 4
- Genital mycotic infections (6% incidence, more common in women) 1
- Home glucose monitoring for first 4 weeks to assess glycemic response 4
If on insulin or sulfonylurea: Consider reducing insulin dose by 20% or sulfonylurea by 50% when initiating the new SGLT2 inhibitor to minimize hypoglycemia risk 4.
Renal Function Considerations
Check his eGFR before switching:
- eGFR ≥45 mL/min/1.73 m²: Either empagliflozin or dapagliflozin can be initiated 1
- eGFR 30-44 mL/min/1.73 m²: Dapagliflozin 10 mg is preferred (empagliflozin not recommended for initiation below 45) 1
- eGFR 25-29 mL/min/1.73 m²: Dapagliflozin 10 mg only 1
- eGFR <25 mL/min/1.73 m²: Do not initiate SGLT2 inhibitor 1
Alternative Class: GLP-1 Receptor Agonists
If SGLT2 inhibitors remain cost-prohibitive or are contraindicated, consider adding a GLP-1 receptor agonist instead 1, 4, 6:
Semaglutide 0.25 mg SC weekly (titrate to 0.5-1 mg weekly) 4
- Superior A1c reduction compared to SGLT2 inhibitors
- Significant weight loss benefit
- Reduces MACE and stroke risk 1, 4
- No renal dose adjustment needed 1
Dulaglutide 0.75-1.5 mg SC weekly 1
- Cardiovascular benefit proven
- No renal adjustment needed
- Once-weekly dosing
What NOT to Do
Do not switch to:
- DPP-4 inhibitors (sitagliptin, saxagliptin): Inferior glycemic control, no cardiovascular benefit, and saxagliptin increases heart failure risk 7, 6
- Sulfonylureas: Cause weight gain, hypoglycemia, and no cardiovascular benefit 8, 6
- Thiazolidinedones (pioglitazone): Cause weight gain, fluid retention, heart failure, and bone fractures 7, 8
Common Pitfalls to Avoid
- Don't abandon SGLT2 inhibitor class entirely due to insurance issues—the cardiovascular and renal benefits are too significant 1, 2
- Don't forget to educate about genital hygiene to reduce mycotic infection risk 2, 4
- Don't continue SGLT2 inhibitor during acute illness (sick day rules: hold during dehydration, surgery, or severe illness to prevent ketoacidosis) 2, 4
- Don't ignore foot care education even with non-canagliflozin SGLT2 inhibitors 4